The core generic pharma business of Strides is led by IP-driven product licensing and marketing and distribution partnerships across the globe. We have leveraged our expertise in niche, difficult-to-develop and manufacture products to emerge as a preferred finished dosage player. Strides has created an exhaustive pipeline of generics across varied formats and domains including oral dosage forms and topicals. We are one among the leading players worldwide in soft gel capsules.

Our domain strategy of developing a comprehensive product portfolio in complex therapeutic segments has attracted marquee partnerships in Regulated markets such as US, Europe, Australia, Canada and S. Africa.

Our efforts on automation in the areas of manufacturing and laboratory has resulted in more activities coming in the scope of automated environment for us, and thus complementing our initiatives for greater compliance. We are now poised for leveraging these actions for more extensive actions for maximizing the benefits and thus creating a more rewarding and conducive environment for Quality and Compliance.

We have also increased our Data and Compliance governance mechanisms and used them effectively for continuous improvements. The risk management process has been enhanced by bringing newer areas or domains into the risk management process, so to address the concerns where needed systematically.